Baymark Expands into Canada with Acquisition of Canadian Addiction Treatment Centers


Lewisville, Texas (March 5, 2018) – BayMark Health Services, a portfolio company of Webster Capital and leading provider of opioid treatment services, announced today that it has acquired Canadian Addiction Treatment Centers (CATC), the largest provider of opioid treatment services in Canada with more than 70 facilities serving over 14,000 patients a day.

Dave White, CEO of BayMark, remarked, “As an organization, CATC provides exceptional care to the Ontario region and we view this partnership as an opportunity to provide care to the broader Canadian population.” Webster Managing Partner, David Malm, said, “The state of opioid abuse in Canada is second only to the United States and the BayMark team is focused on combating this pressing societal issue.”

“Partnering with BayMark allows us to bring more resources to fight the opioid epidemic here in Ontario and in new geographies across Canada while pairing us with an organization that has the same commitment to high quality care,” said Cam Crawford, Chief Executive Officer of CATC. “We are thrilled about the partnership and believe this will allow us to even better serve our patient base.”

BayMark has expanded into 25 states and 1 province in North America and is the largest opioid treatment company in North America with 167 programs. Webster invested in BayMark in 2015 with the goal of providing care to those impacted by opioid abuse.

About BayMark Health Services
BayMark Health Services, headquartered in Lewisville, Texas, provides medication-assisted treatment to more than 45,000 patients in recovery from opioid use disorder. The Company’s outpatient programs deliver medically supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of prescription pain medication or other opioids. The BayMark continuum of patient- focused services includes highly structured opioid treatment programs utilizing methadone or buprenorphine and office-based buprenorphine programs, both of which incorporate counseling as part of an individualized treatment plan; as well as, ambulatory withdrawal management services with naltrexone therapy, residential treatment and recovery support services. For further information, please visit

About Webster Capital
Founded in 2003, Webster Capital is a private equity partnership which helps companies unlock their potential. Webster focuses on branded consumer and healthcare services companies with EBITDA between $3 million to $15 million. Webster Capital provides equity financing, expertise, and a broad contact network for management buyouts and growth capital. Webster has raised $600 million and is currently investing Fund III, a $400 million fund raised in 2014. For additional information on Webster Capital, please visit